Who
Robert Iannone
EVP, Global Head of R&D & CMO
Company insider
Files Form 4 as: EVP, Global Head of R&D & CMO, Jazz Pharmaceuticals; Director, Pliant Therapeutics; Director, Autolus Therapeutics; Director, iTeos Therapeutics; Director, Jounce Therapeutics; Chief Medical Officer, Immunomedics.
In numbers
- Trades disclosed
- 91
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $41.2M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 14 Sep 2018
- Last trade
- 27 Aug 2026
- Last filed
- 31 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $3.0M26,116 at $113.10 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $76K300 at $252.76 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —884 at $0.00 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,916 at $0.00 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —26,116 at $0.00 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —27,584 at $0.00 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $100K884 at $113.10 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $3.8M27,584 at $137.12 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —884 at $0.00 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,916 at $0.00 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —26,116 at $0.00 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —27,584 at $0.00 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $400K2,916 at $137.12 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $4.5M18,187 at $247.86 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.8M11,423 at $248.67 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $4.5M18,113 at $250.02 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $4.9M19,639 at $250.60 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $2.3M9,259 at $251.95 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $3.0M26,116 at $113.10 | filing |
| 27 Aug 2026filed 31 Aug 2026 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $100K884 at $113.10 | filing |
News
Jazz Pharmaceuticals Reports Positive Phase 3 Results For Ziihera CombinationJAZZ · finanzen.ch · 23 Oct 2026Jazz Pharmaceuticals gets Cramer's vote of confidenceJAZZ · aol.com · 14 Oct 2026Critical Analysis: vTv Therapeutics (NASDAQ:VTVT) and Jazz Pharmaceuticals (NASDAQ:JAZZ)JAZZ · tickerreport.com · 12 Oct 2026
0 headlines in the last 90 days name Robert Iannone; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.